Answering the Questions on Switching ART With Virologic Suppression

In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:

• Switching with prior or unknown resistance
• Data on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studies
• The impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 study
• A post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistance
• Data from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184V
• A retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat’AIDS Cohort
• Switching to long-acting ART
• Guidance on candidates for LA CAB + RPV
• Data on risk factors for virologic failure with LA CAB + RPV
• Considering an ART switch after weight gain
• Data on weight gain after ART initiation by ARV class and drug
• Mean change in weight by sex at Week 96 in the ADVANCE study
• DHHS guideline recommendations regarding weight gain with ART